Lexaria Bioscience Says Australian Tax Refund And Institutional Financing Priced At $12.92/Share Yielded $7.9M Net, About $4.60/Share In Cash On 2.1 Million Shares Outstanding; Says No Further Financings Planned In 2026

Lexaria Bioscience shares are trading higher after the company announced an update on its financial position, showing cash on hand reaching ~$4.60 per share following $7.9 million in recent net proceeds.

8-K filing — Lexaria Bioscience Corp. (LEXX)

Filed: 2026-09-09 AccNo: 0001640334-26-001468 Size: 518 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today.